View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 6, 2020updated 22 Nov 2021 6:08am

BMS to acquire biopharma firm MyoKardia for $13.1bn

Bristol Myers Squibb (BMS) has signed a definitive merger agreement to acquire clinical-stage biopharma firm MyoKardia in a cash-based transaction valued at $13.1bn.

Bristol Myers Squibb (BMS) has signed a definitive merger agreement to acquire clinical-stage biopharma firm MyoKardia, in a cash-based transaction valued at $13.1bn.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

Under the deal, BMS will purchase all the outstanding shares of MyoKardia’s common stock for $225 per share.

MyoKardia focuses on the discovery and development of targeted treatments for critical cardiovascular diseases.

Under the agreement, BMS will secure MyoKardia’s investigational cardiovascular drug, mavacamten, which has the potential to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM).

HCM is a chronic, progressive heart disease characterised by excessive heart muscle contraction and decreased left ventricle’s ability to fill, resulting in debilitating symptoms and cardiac dysfunction.

The company plans to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) in the first quarter of next year for the use of mavacamten in this indication.

The submission will derive from the results from the Phase III EXPLORER-HCM trial, where mavacamten met the primary and secondary endpoints.

Also, the drug candidate demonstrated meaningful improvements in symptoms, functional status and quality of life by mitigating the obstruction of blood flow from the heart.

Anticipating medium-and long-term growth driver possibilities of mavacemten, BMS plans to analyse the full potential of the drug candidate in other indications such as non-obstructive HCM.

BMS will develop MyoKardia’s portfolio of pipeline candidates, including two clinical-stage therapies, danicamtiv (MYK-491) and MYK-224.

In addition to complimenting BMS’ portfolio and pipeline, the acquisition could boost the company’s scientific capabilities.

Bristol Myers Squibb board chair and CEO Giovanni Caforio said: “We are further strengthening our outstanding cardiovascular franchise through the addition of mavacamten, a promising medicine with the potential to address a significant unmet medical need in patients with cardiovascular disease.”

The transaction, subject to customary closing conditions, should conclude during the fourth quarter of this year.

In August, BMS agreed to acquire Forbius, a protein engineering firm that focuses on biotherapeutics to treat cancer and fibrotic diseases.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology